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30-words-abstract: Simultaneous appearance of a pacemaker-lead associated thrombus 
and a left atrial appendage closure device related thrombus in a patient with urothelial 
carcinoma shown in a transesophageal echocardiography 
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figure 1 
 
A 84-year-old male patient underwent routine transesophageal echocardiography five 
months after closure of the left atrial appendage (LAA) using a Watchman™ -Device as an 
alternative stroke prevention strategy in atrial fibrillation and following several bleeding 
complications under oral anticoagulation from an urothelial carcinoma. Immediately after 
closure of the LAA oral anticoagulation had been stopped and the patient remained under 
acetylic salicylic acid. Besides paroxysmal atrial fibrillation, he had a history of coronary 
artery disease with coronary artery bypass grafting 18 years and myocardial infarction ten 
years ago and a moderate aortic stenosis. Five months before, a three-chamber pacemaker 
was implanted for cardiac resynchronization therapy (CRT) for severely reduced systolic left 
ventricular function and left bundle branch block. The actual transesophageal 
echocardiography revealed two intra-cardiac thrombi. The larger thrombus was attached to 
the right ventricular CRT-lead and situated in the right atrium (figure 1, panels A and B: 
arrows pointing at pacemaker lead associated thrombus, 25 x 19 mm; LA: left atrium, RA: 
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right atrium; RV: right ventricle). The second thrombus adhered to the LAA closure device in 
the left atrium (figure 1, panels C and D: thin arrows showing thrombus, 9 x 10 mm; bold 
arrows indicating LAA closure device; LV: left ventricle, CR: coumarine ridge). A patent 
foramen ovale was excluded. The simultaneous appearance of two thrombi in the left and 
the right atrium was assumed to be caused by increased, possibly paraneoplastic, 
hypercoagulable conditions in this patient suffering from urothelial carcinoma [1]. A large 
meta-analysis underlined, that in patients with cancer-associated thrombosis, low-molecular 
weight heparins (LMWH) reduce the recurrence of venous thromboembolism (VTE) as 
compared to vitamin-K antagonists, whereas direct oral anticoagulants (DOAC) do not [2]. 
However, a very recently published cohort study including 200 patients with cancer-
associated VTE treated with rivaroxaban has suggested preserved safety and efficacy, but 
this study lacked of a control group and outcomes were compared with past-published data 
on LMWHs [3]. Still, actual recommendations on DOACs advise caution when used in cancer 
patients [4]. As evidence for the treatment of device-related thrombosis other than central 
venous catheter-associated thrombosis in patients with cancer is limited, the presented 
patient was referred to the regional hospital for the initiation of an anticoagulation using 
(low-molecular weight) heparins, in accordance to current recommendations on the 
treatment of cancer-associated VTE [5-6]. 
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Additional material (for possible online publication only) 
1) 3D-TEE movie showing the pacemaker lead associated thrombus 
  
2) 2D-TEE movie of the pacemaker lead associated thrombus 
 
3) 2D-TEE movie of the LAA closure device thrombus 
 
 
